Leishmaniasis Treatment Market Expected to Raise at CAGR of 8.8% by 2019-2026 | Top Companies - Sanofi S.A., Sequus Pharmaceuticals Inc., Paladin Labs Inc., Gland Pharma Limited, etc.

According to the current analysis of Reports and Data, the global Leishmaniasis Treatment market was valued at USD 104.8 million in 2018 and is expected to reach USD 206.5 million by the year 2026, at a CAGR of 8.8%. A disease outbreak takes place when a disease escalates by a higher number than expected in a region or during a season. An outbreak may occur in one community or even extend to several countries altogether.

Avail the inside scoop of the Sample report @ https://www.reportsanddata.com/sample-enquiry-form/2153

Companies considered and profiled in this market study

Sanofi S.A., Sequus Pharmaceuticals Inc., Paladin Labs Inc., Enzon Pharmaceuticals Inc., Gland Pharma Limited, Gilead Life sciences and Lifecare Innovations Private Limited.

There was a time when people in all countries and on all continents remain chronically vulnerable to infectious diseases, known and unknown. Leishmaniasis was the neglected tropical disease (NTD) that has threatened the people worldwide as per the WHO. Leishmaniasis is a major complex of protozoal vector-borne diseases that affects both humans and animals. The disease is caused by different species of Leishmania, and it is manifested by three major clinical forms named as cutaneous, mucosal and visceral leishmaniasis. Leishmaniasis is transmitted by the bite of infected female sand flies. In each of these forms, infection ranges from causing no symptoms (asymptomatic infection) to severe, even life-threatening complications.

According to the National Organization of Rare Disorders, only a small percentage of people infected by Leishmania parasites will go on to actually develop the disease. There is uneven global distribution of the disease often because of the various distribution pattern of the parasite, the vector and the reservoir host species. Efforts to increase visceral leishmaniasis surveillance, vector control, diagnosis, and treatment are making important progress all across the world. In 2012, WHO launched an action plan for reducing the impact of Neglected Tropical Diseases (NTDs), including visceral leishmaniasis. Leishmaniasis is seldom encountered in the United States.

Further key findings from the report suggest
1. North America is expected to account for the largest market share of 2% of the Leishmaniasis treatment market, owing it to the prevalence of unhealthy lifestyle, high number of target diseases, rise in number of product approval by FDA, ongoing clinical trials, and favorable government regulations scenario contributing to the development of healthcare and therapeutics

2. Europe is the second largest regional segment with the market share of 28.4% in 2018, due to the increased awareness of availability of different therapies and drugs for the treatment and rising awareness about innovations and advancements in Leishmaniasis treatment in pharmaceutical molecules, coupled with increasing incidences of target diseases across the world

Ask Here to Get customization & Check for irresistible discount rates on this report @ https://www.reportsanddata.com/discount-enquiry-form/2153

For the purpose of this report, Reports and Data has segmented the Leishmaniasis Treatment market on the basis of Disease type, pathological tests, therapy type, end use and region:

Disease Type (Revenue, USD Million; 2016-2026)
Cutaneous Leishmaniasis
Mucosal Leishmaniasis
Visceral Leishmaniasis

Pathological tests (Revenue, USD Million; 2016-2026)
By Serological Tests
Parasitological Evaluation
DNA- Based Methods
Immunological Methods
Others

Therapy type (Revenue, USD Million; 2016-2026)
By Drug Therapy
Pentavalent Antimonials
Antifungal
Antibiotics
By Non-Drug Therapy

End Use Revenue, USD Million; 2016-2026)
Hospitals
Clinics
Diagnostic Laboratory
Others

Regional Outlook (Revenue, USD Million; 2016-2026)
North America
Europe
Asia Pacific
Latin America
Middle East and Africa (MEA)

Access the Entire Report packed with TOC, Tables and Figures and Outline of Prominent Companies @ https://www.reportsanddata.com/report-detail/leishmaniasis-treatment-market

Key selling points of this research study
1. The study gives an in-depth evaluation of the evolving competitive scenario that gives the reader/client a competitive edge.

2. It offers a holistic view of all critical aspects boosting or limiting the growth of the sector

3. The market intelligence report derives an eight-year forecast, including historical, contemporary, and potential market prospects, projecting the estimated progress of the market.

4. It aids informed decision-making by offering an exhaustive database of the pivotal market segments and sub-segments

Contact Us:

John Watson
Head of Business Development
Reports And Data
40 Wall St. 28th floor New York City, NY 10005 United States
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

This release was published on openPR.